Is cefaclor appropriate for treating an uncomplicated skin infection?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Is Cefaclor Appropriate for Skin Infections?

Yes, cefaclor is an acceptable option for uncomplicated skin and soft tissue infections caused by susceptible organisms, specifically Staphylococcus aureus and Streptococcus pyogenes, though it is not a first-line agent in the modern treatment landscape.

Evidence-Based Recommendation

The FDA label explicitly lists skin and skin structure infections caused by S. aureus and S. pyogenes as approved indications for cefaclor 1. However, this approval must be contextualized within current treatment guidelines and the evolving resistance landscape.

When Cefaclor Is Appropriate

For mild, uncomplicated skin infections in outpatient settings where MRSA is not suspected, cefaclor can be used effectively:

  • The 2014 IDSA guidelines for skin and soft tissue infections recommend cephalexin (not cefaclor specifically) as a preferred oral cephalosporin for non-purulent cellulitis and impetigo 2
  • Clinical studies demonstrate cefaclor achieves 96-99% cure rates in skin infections with excellent pathogen eradication 3, 4, 5, 6
  • The drug shows particular efficacy against methicillin-susceptible S. aureus (MSSA) and streptococcal infections 5

Critical Limitations and Caveats

Cefaclor has NO activity against MRSA - this is the most important clinical pitfall 2. The IDSA guidelines clearly state that for purulent infections (abscesses, carbuncles) where MRSA is likely, you need anti-MRSA coverage with agents like trimethoprim-sulfamethoxazole, doxycycline, or clindamycin 2.

Practical decision algorithm:

  • Non-purulent cellulitis (diffuse erythema, warmth, no abscess) → Cefaclor is acceptable, though cephalexin is preferred per guidelines 2
  • Purulent infection (abscess, carbuncle, furuncle) → Do NOT use cefaclor; use anti-MRSA agents 2
  • Failed initial therapy or systemic signs (fever, tachycardia, hypotension) → Do NOT use cefaclor; escalate to anti-MRSA coverage 2

Comparative Context

While cefaclor works, cephalexin is the preferred oral cephalosporin in the IDSA guidelines because it requires less frequent dosing (4 times daily for both, but cephalexin has better established data) and is specifically mentioned in the guideline tables 2. Cefaclor's twice-daily advanced formulation may offer compliance advantages 4, but this formulation availability varies.

Safety Profile

Cefaclor is generally well-tolerated with adverse effects in only 2.5% of patients 1. The most concerning reaction is serum sickness-like syndrome, occurring in 0.024-0.5% of patients, more commonly in children on repeat courses 1. This manifests as rash, arthralgia, and fever days after starting therapy and typically resolves quickly after discontinuation.

Bottom Line for Clinical Practice

Use cefaclor only when:

  • The infection is clearly non-purulent cellulitis
  • MRSA risk is low (no prior MRSA, no recent antibiotics, no healthcare exposure)
  • Culture and susceptibility confirm susceptible organisms 1
  • Preferred agents (cephalexin, dicloxacillin) are unavailable or contraindicated

Do NOT use cefaclor for:

  • Any purulent skin infection where MRSA is possible
  • Patients who failed initial antibiotic therapy
  • Severe infections with systemic symptoms
  • Empiric therapy in areas with high MRSA prevalence

The drug works effectively when appropriately selected, but modern resistance patterns and guideline recommendations favor other agents as first-line choices for most skin infections.

References

Related Questions

Is cefixime appropriate for treating an uncomplicated bacterial skin infection, and what dosage and monitoring are recommended?
Is cefpodoxime appropriate for treating a soft‑tissue infection?
Does cefpodoxime provide coverage against Staphylococcus epidermidis?
What is the recommended oral cefpodoxime dose and duration for uncomplicated cellulitis in an adult without drug allergies, and in which situations would cefpodoxime be inappropriate?
What is the appropriate cefdinir dosing for a 3-year-old child with cellulitis?
What intravenous fluid and potassium chloride dosing regimen should be used to treat hypokalemia?
I have had dermatitis of both axillae for over a month, unresponsive to fenistil and Bepanthen; should I use mometasone furoate 0.1% topical corticosteroid, and what duration and dosing frequency is appropriate?
In a patient with chronic cellulitis and a non‑healing wound, when is daily prophylactic antibiotic therapy indicated and what regimen is recommended?
If my bilateral axillary dermatitis clears before completing a 2‑week course of topical mometasone furoate 0.1%, can I stop the medication?
What is the likely diagnosis and recommended emergency treatment for a 6‑month‑old infant weighing 6.8 kg who presents afebrile with upward eye rolling and sudden stiffness of the arms and legs?
What are occlusive conditions and should they be avoided when treating bilateral axillary dermatitis with mometasone furoate (0.1%)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.